Site Map | Contact Us | Request More Information | Buying Information
Copyright and Terms of Service
Copyright
© Copyright 2009 Baxter Healthcare Corporation. All rights reserved.
All content and images used on this site are owned or licensed by Baxter International Inc.or its affiliates ("Baxter") for use on this site only. Unauthorized use is prohibited.
Terms of Service
Disclaimer
The information on Hylenex.com is provided "as is" without any warranties, expressed or implied. In particular, Baxter makes no representation or warranty that the information contained on this site will be timely, complete or error-free. To the extent permitted by applicable laws, Baxter accepts no liability whatsoever in respect of any loss, damage or expenses arising from your use of this site or the unavailability of this site.
Applicable Laws
This site contains information about treatments and therapies, which may or may not be available in other countries. Each country has specific laws, regulations and medical practices governing the communication of medical or other information on the Internet. Nothing in this site should be viewed as a solicitation or promotion of any particular treatment or therapy, which is not authorized, by the laws and regulations of the country where the reader resides, or as a promotion or advertisement of any products or services.
Health Information
This site contains information on medical and health-related topics. This information is not meant to be a substitute for the advice provided by physicians or other medical professionals. You should not use this information for diagnosing a health problem or disease but should always consult a physician.
Links to Other Web Sites
Baxter can direct you to external web sites. Baxter does not own these sites. Baxter does not necessarily endorse and is not responsible for the content of any offsite pages or any other sites linked to these sites. Use of linked sites that are not owned or operated by Baxter is at your own risk and Baxter will not be liable for any loss, damage or expenses, which you suffer or incur as a result of your use of such sites.
Confidentiality and Security on the Internet
Baxter has taken measures to ensure the security and confidentiality of any information that you provide to this site, the Internet is not an absolutely secure medium, and is not under Baxter's control. Use of the Internet is solely at your own risk and is subject to the applicable laws and regulations. For details of the way in which Baxter deals with information relating to you, please refer to the Privacy Policy.
Variations to These Terms and Conditions
Baxter may, from time to time, make changes to these terms and conditions. However, you will be informed of such changes by a notice on this site.
Trademarks
Baxter, Hylenex, and the Hylenex logo are registered trademarks of Baxter International Inc. Any other brands or trademarks that may appear herein are the property of their respective owners.
Nothing contained herein shall be construed as conferring any license or right under any Baxter patent, copyright or trademark.
Important Risk Information for Healthcare Professionals
Indications
HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for subcutaneous fluid administration; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.
Important Risk Information
- Hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product.
- Discontinue HYLENEX recombinant (hyaluronidase human injection) if sensitization occurs.
- Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
- Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.
- Hyaluronidase should not be used to reduce the swelling of bites or stings.
- Hyaluronidase should not be applied directly to the cornea.
- Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.
- Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.
- The most frequently reported adverse experiences have been mild local injection site reactions, such as erythema and pain.
- Hyaluronidase has been reported to enhance the adverse events associated with co-administered drug products.
- Allergic reactions (urticaria or angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase.
- Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
- When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidence of systemic reaction.
- Edema has been reported most frequently in association with subcutaneous fluid administration.
- The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. As with all parenteral fluid therapy, use the same precautions for restoring fluid and electrolyte balance.
- During subcutaneous fluid administration, special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion.
- When solutions devoid of inorganic electrolytes are given subcutaneously, hypovolemia may occur.
